Brilinta Tablets 60mg/90mg Clinical Experience Investigation
Brilinta Tablets 60mg/90mg Clinical Experience Investigation
To confirm the following safety topics in patients to be treated with BRILINTA tablets 60 mg or 90 mg (hereinafter referred to as "BRILINTA") in clinical practice in the post-marketing phase.
Inclusion Criteria:
Exclusion Criteria:
-
Gunma, 371-0811, Japan
Gunma, 371-0821, Japan
Hokkaido, 004-0052, Japan
Hokkaido, 006-0811, Japan
Hokkaido, 061-1373, Japan
Hokkaido, 063-0005, Japan
Hokkaido, 078-8211, Japan
Hokkaido, 093-0076, Japan